Senior Director, Global Patient Safety Surveillance

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity: The Senior Director of Safety Surveillance is a senior member of the Surveillance team serving as a line leader of their team and subject matter expert for the design, development, maintenance, and support of core Global Patient Safety (GPS) processes. This individual will oversee and/or lead safety development activities including scientific innovation and enablement across various disciplines relevant to clinical safety and pharmacovigilance, such as but not limited to safety risk management, signal detection & management, comparative benefit-risk, and aggregate reporting. The Senior Director of Safety Surveillance serves in a critical enabling and strategic position, ensuring that Revolution Medicines continuously delivers effective scientific safety activities and/or pharmacovigilance (PV) activities, in line with health authority and internal stakeholder requirements. The Senior Director of Safety Surveillance will have an extensive understanding of all aspects of the internal and external operating environment, which will enable anticipation of new developments and implementation of improvements critical to process maintenance and refinement at Revolution Medicines.

Responsibilities include:

• Establish and provide effective leadership, mentorship, and accountability for an experienced global team and for the quality of their work in building and maintaining safety processes and other safety development activities according to the values of Revolution Medicines.
• Management of team resources under their responsibility are deployed according to the priorities of GPS and for the improvement of PV system quality.
• Provide relevant subject matter expertise for the design, development, maintenance, and support of one or more core GPS processes (i.e. comparative benefit-risk, signal detection & management, risk management, aggregate reporting, etc.) in compliance with applicable Good Clinical Practice (GCP), Good Pharmacovigilance Practice (GVP), Good Documentation Practices (GDocP), etc., in alignment with the company’s mission and objectives.
• Provide strategic direction and leadership where necessary to the GPS team and cross-functional Development staff to manage the core safety processes and support the execution/delivery of the required outputs (e.g. Risk Management Plans (RMPs), Developmental Safety Update Reports (DSURs), Periodic Safety Update Reports (PSURs), etc.) in compliance with global regulatory requirements and following best practices.
• Provide expert consultation and direction for Development and filing teams where impactful as it relates to PV portions of regulatory reports and clinical study documents (including Clinical Protocols, Informed Consent Forms, Investigator Brochures, NDA filing packages (i.e. Module 2: Clinical Overview, Clinical Summary, Integrated Summary of Safety (ISS), Integrated Summary of Efficacy (ISE), safety narratives), and labeling strategy.
• Lead and/or oversee the development of controlled documentation required to demonstrate control and oversight of the PV aggregate reporting process and other processes as needed.
• Work with the EU Qualified Person Responsible